SEC Form 4 · accession 0001470831-26-000813
Bicara Therapeutics Inc. · BCAX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Claire Mazumdar
Officer — Chief Executive Officer · Director
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 4:19 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0002023658
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2026 | M | 10,000 | $3.7898 | A | 372,152 | D | |
| Common StockF2 | Aug 10, 2026 | S | 10,000 | $27.975 | D | 362,152 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.7898 | Aug 10, 2026 | M | 10,000 | D | — | Apr 5, 2033 | Common Stock | 10,000 | 110,546 | D |
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.